Literature DB >> 14616331

Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects.

S Refstad1.   

Abstract

Among young people in Norway the recreational use of amphetamine derivatives seems to be increasing. Methylenedioxymethamphetamine (MDMA), known as ecstasy, is the dominant substance, having both stimulant and psychedelic properties. Depending on the illegal source of these so-called 'party drugs' the content and purity can vary. This case report describes the first lethal case of paramethoxyamphetamine (PMA) and paramethoxymethamphetamine (PMMA) intoxication reported in Norway. A 16-year-old male was admitted to a local hospital in a coma with seizures and hyperthermia after he had been found undressed and barefooted in a local forest (temperature 2 degrees C). He was intubated and given supportive care. Blood chemistry revealed hypoglycaemia, hypocalcaemia and hyperkalaemia. Shortly after transfer to the central hospital he developed bradycardia with continuous seizures and asystole. Adverse effects of MDMA are well described and include serotonergic and sympathomimetic symptoms with hyperthermia, coagulopathy, rhabdomyolysis and acute kidney and liver failure. Case reports of PMA deaths collectively suggest PMA to be more toxic than MDMA. A delayed effect after intake of PMA compared with MDMA can lead to increased intake. Hypoglycaemia and hyperkalaemia may be specific to PMA poisoning. Increased thermo genesis will result in a search for cooling, which explains the attempt to undress and a desire to submerge in water. In a cool climate this behaviour itself can be lethal. Measures to treat seizures, hypoglycaemia, electrolyte anomalies and hyperthermia are the therapeutic goals. No specific treatment is available.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14616331     DOI: 10.1046/j.1399-6576.2003.00245.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  7 in total

Review 1.  Hypoglycemia in critically ill children.

Authors:  E Vincent S Faustino; Eliotte L Hirshberg; Clifford W Bogue
Journal:  J Diabetes Sci Technol       Date:  2012-01-01

2.  Deaths from exposure to paramethoxymethamphetamine in Alberta and British Columbia, Canada: a case series.

Authors:  Jennifer J E Nicol; Mark C Yarema; Graham R Jones; Walter Martz; Roy A Purssell; Judy C MacDonald; Ian Wishart; Monica Durigon; Despina Tzemis; Jane A Buxton
Journal:  CMAJ Open       Date:  2015-01-13

Review 3.  Postmortem diagnosis of hyponatremia: case report and literature review.

Authors:  Jessica Vanhaebost; Cristian Palmiere; Maria Pia Scarpelli; Fabiola Bou Abdallah; Arnaud Capron; Gregory Schmit
Journal:  Int J Legal Med       Date:  2017-05-13       Impact factor: 2.686

Review 4.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  Comparative potencies of 3,4-methylenedioxymethamphetamine (MDMA) analogues as inhibitors of [3H]noradrenaline and [3H]5-HT transport in mammalian cell lines.

Authors:  T Montgomery; C Buon; S Eibauer; P J Guiry; A K Keenan; G J McBean
Journal:  Br J Pharmacol       Date:  2007-09-24       Impact factor: 8.739

6.  Effects of MDMA on body temperature in humans.

Authors:  Matthias E Liechti
Journal:  Temperature (Austin)       Date:  2014-10-31

7.  Methylphenidate has mild hyperglycemic and hypokalemia effects and increases leukocyte and neutrophil counts.

Authors:  Gideon Charach; Eli Karniel; Itamar Grosskopf; Alexander Rabinovich; Lior Charach
Journal:  Medicine (Baltimore)       Date:  2020-07-02       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.